MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone loss
Abstract Objective Diabetic osteoporosis is a secondary complication of diabetes mellitus, characterized by reduced bone mass, increased bone fragility, and impaired fracture healing. However, the mechanisms underlying diabetic bone loss remain to be fully elucidated. More importantly, there is an u...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2026-01-01
|
| Серія: | Journal of Translational Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12967-026-07699-w |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|